SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (5514)1/22/2002 10:38:46 AM
From: michael97123  Respond to of 52153
 
Thank you Peter. There is a big difference however between a drug that works modestly well and one that is a blockbuster. Thats what the fudging may have been intended to resolve. My reference to enron related more to company management. Is there any doubt that the Waksals would have been shredding also if they had run enron? After watching specific tech stocks that i owned implode last year, i have little doubt that imcl could wind up in high single digits before this ends. Good luck to all. mike



To: Biomaven who wrote (5514)1/22/2002 11:57:25 AM
From: Robohogs  Read Replies (2) | Respond to of 52153
 
Peter -

Any thoughts on the Elan Alzheimers news? Seems weird that all four problems in one subset in France. Sounds like a virus or contamination or some other factors. $2.3 B gone for a drug which at best is 2006 and which is a fraction of the Alzheimers franchise.

Jon


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News